Investor presentation in March indicated a phase 1 capital cost of $87.6 million, now the DFS says $154.8 million.This discrepancy might be the reason for the lacklustre market response - maybe I am reading it wrong.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025